Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 2/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5955239 | 0.97 | CDK2 (0.44) | CDK2MGLLLMNAALDH1A1MEN1 | |
| SCHEMBL5955006 | 0.94 | MGLL (0.50) | MGLLLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL5954387 | 0.92 | MGLL (0.49) | MGLLLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL5954470 | 0.92 | MGLL (0.49) | MGLLLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL5954389 | 0.92 | MGLL (0.49) | MGLLLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL5954383 | 0.92 | MGLL (0.49) | MGLLLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL5954376 | 0.90 | ALDH1A1 (0.46) | MGLLLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL5954397 | 0.89 | NPBWR1 (0.40) | CDK2LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL5954469 | 0.89 | ABCB1 (0.47) | MGLLLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL5955343 | 0.89 | ABCB1 (0.47) | MGLLLMNAALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060025589-A1 | 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes | LABORATOIRES FOURNIER S.A. (FR) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025589-A1 | 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes | LIPC, CYP4F2, SLC5A2 | CDK2 1913/4885MGLL 432/4885LMNA 3718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.